Kodama K, Pasche B, Olsson P, Swedenborg J, Adolfsson L, Larm O, Riesenfeld J
Department of Experimental Surgery, Karolinska Sjukhuset, Stockholm, Sweden.
Thromb Haemost. 1987 Dec 18;58(4):1064-7.
The mode of F Xa inhibition was investigated on a thromboresistant surface with end-point attached partially depolymerized heparin of an approximate molecular weight of 8000. Affinity chromatography revealed that one fourth of the heparin used in surface coating had high affinity for antithrombin III (AT). The heparin surface adsorbed AT from both human plasma and solutions of purified AT. By increasing the ionic strength in the AT solution the existence of high and low affinity sites could be shown. The uptake of AT was measured and the density of available high and low affinity sites was found to be in the range of 5 and 11 picomoles/cm2, respectively. Thus the estimated density of biologically active high and low affinity heparin respectively would be 40 and 90 ng/cm2. The heparin coating did not take up or exert F Xa inhibition by itself. With AT adsorbed on both high and low affinity heparin the surface had the capacity to inhibit several consecutive aliquots of F Xa exposed to the surface. When mainly high affinity sites were saturated with AT the inhibition capacity was considerably lower. It was demonstrated that the density of AT on both high and low affinity heparin determines the F Xa inhibition capacity whereas the amount of AT on high affinity sites limits the rate of the reaction. This implies that during the inhibition of F Xa there is a continuous surface-diffusion of AT from sites of a lower class to the high affinity sites where the F Xa/AT complex is formed and leaves the surface. The ability of the immobilized heparin to catalyze inhibition of F Xa is likely to be an important component for the thromboresistant properties of a heparin coating with non-compromised AT binding sequences.
在具有末端连接的部分解聚的、分子量约为8000的肝素的抗血栓表面上研究了因子Xa(F Xa)的抑制模式。亲和层析显示,用于表面涂层的肝素中有四分之一对抗凝血酶III(AT)具有高亲和力。肝素表面从人血浆和纯化的AT溶液中吸附AT。通过增加AT溶液中的离子强度,可以显示出高亲和力和低亲和力位点的存在。测量了AT的摄取量,发现可用的高亲和力和低亲和力位点的密度分别在5和11皮摩尔/平方厘米范围内。因此,估计的具有生物活性的高亲和力和低亲和力肝素的密度分别为40和90纳克/平方厘米。肝素涂层本身不摄取或发挥F Xa抑制作用。当高亲和力和低亲和力肝素上都吸附有AT时,该表面有能力抑制暴露于该表面的几批连续的F Xa。当主要是高亲和力位点被AT饱和时,抑制能力会大大降低。结果表明,高亲和力和低亲和力肝素上AT的密度决定了F Xa抑制能力,而高亲和力位点上AT的量限制了反应速率。这意味着在F Xa抑制过程中,AT从低等级位点持续向高亲和力位点进行表面扩散,在高亲和力位点形成F Xa/AT复合物并离开表面。固定化肝素催化F Xa抑制的能力可能是具有完整AT结合序列的肝素涂层抗血栓特性的一个重要组成部分。